Azalea Vision, a Ghent, Belgium-based ocular health company, closed €15M Series A funding round, raising a €9M extension.
Backers SPRIM Global Investments and Afrimobility.
The company intends to use the funds to support the execution of its First-in-human (FIH) pilot clinical trial, a key milestone in establishing the safety and performance of its medically intelligent ocular technology platform.
Led by CEO Enrique Vega, Azalea Vision is an ocular health company building a solution for complex vision conditions, remote diagnostics, and targeted ocular therapies. It develops a medical-grade smart lens platform designed to sense, adapt, and interact in real time.
The company, which was founded in 2021 as a spin-off from imec and Ghent University, also announced the appointment of Robert J. Dempsey as Chairman of the Board to guide strategic growth in the European and U.S. markets.
Commenting on the news, Enrique Vega said: “Additional funding in this round from SPRIM Global Investments and Afrimobility, along with a strategic investor who remains undisclosed, further emphasizes the confidence in our platform. The appointment of Robert J. Dempsey, a highly regarded leader in the ophthalmic space, brings deep domain expertise and strong industry relationships to guide our leadership team as we move forward into our next stage of growth.”
FinSMEs
29/04/2025